BR0315939A - Métodos para tratar ou prevenir degeneração macular em um paciente e maculopatia relacionada com idade, neovascularização coroidal, descolamento do epitélio de pigmento ou atrofia de epitélio de pigmento retinal e composição farmacêutica - Google Patents

Métodos para tratar ou prevenir degeneração macular em um paciente e maculopatia relacionada com idade, neovascularização coroidal, descolamento do epitélio de pigmento ou atrofia de epitélio de pigmento retinal e composição farmacêutica

Info

Publication number
BR0315939A
BR0315939A BR0315939-6A BR0315939A BR0315939A BR 0315939 A BR0315939 A BR 0315939A BR 0315939 A BR0315939 A BR 0315939A BR 0315939 A BR0315939 A BR 0315939A
Authority
BR
Brazil
Prior art keywords
methods
treating
preventing
macular degeneration
age
Prior art date
Application number
BR0315939-6A
Other languages
English (en)
Inventor
Jerome B Zeldis
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR0315939A publication Critical patent/BR0315939A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"MéTODOS PARA TRATAR OU PREVENIR DEGENERAçãO MACULAR EM UM PACIENTE E MACULOPATIA RELACIONADA COM IDADE, NEOVASCULARIZAçãO COROIDAL, DESCOLAMENTO DO EPITéLIO DE PIGMENTO OU ATROFIA DE EPITéLIO DE PIGMENTO RETINAL E COMPOSIçãO FARMACêUTICA". A presente invenção refere-se aos métodos para tratar, prevenir, controlar a degeneração macular (MD). Modalidades específicas incluem a administração de um inibidor de JNK, sozinho ou em combinação com um segundo agente ativo e/ou com terapia cirúrgica ou física. Composições farmacêuticas, formas de dosagem unitárias individuais, e kits adequados para uso nos métodos da invenção também são descritos.
BR0315939-6A 2002-10-31 2003-10-31 Métodos para tratar ou prevenir degeneração macular em um paciente e maculopatia relacionada com idade, neovascularização coroidal, descolamento do epitélio de pigmento ou atrofia de epitélio de pigmento retinal e composição farmacêutica BR0315939A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42289602P 2002-10-31 2002-10-31
US10/699,105 US20040092568A1 (en) 2002-10-31 2003-10-30 Methods for the treatment, prevention and management of macular degeneration
PCT/US2003/034662 WO2004041191A2 (en) 2002-10-31 2003-10-31 Methods for the treatment, prevention and management of macular degeneration

Publications (1)

Publication Number Publication Date
BR0315939A true BR0315939A (pt) 2005-09-13

Family

ID=32233518

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315939-6A BR0315939A (pt) 2002-10-31 2003-10-31 Métodos para tratar ou prevenir degeneração macular em um paciente e maculopatia relacionada com idade, neovascularização coroidal, descolamento do epitélio de pigmento ou atrofia de epitélio de pigmento retinal e composição farmacêutica

Country Status (11)

Country Link
US (1) US20040092568A1 (pt)
EP (1) EP1565188A2 (pt)
JP (1) JP2006507307A (pt)
KR (1) KR20050061596A (pt)
AU (1) AU2003286802A1 (pt)
BR (1) BR0315939A (pt)
CA (1) CA2504028A1 (pt)
MX (1) MXPA05004550A (pt)
NZ (1) NZ540187A (pt)
TW (1) TW200420290A (pt)
WO (1) WO2004041191A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
ES2284308B1 (es) * 2005-03-08 2008-08-01 Bsh Electrodomesticos España, S.A. Tambor para maquina lavadora de ropa.
WO2008034161A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
US8344018B2 (en) 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
US8134000B2 (en) 2008-07-14 2012-03-13 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
US8088771B2 (en) 2008-07-28 2012-01-03 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene inhibitor compounds
WO2010071230A1 (ja) 2008-12-17 2010-06-24 学校法人慶應義塾 細胞特異的能動集積性を有する光線力学療法剤
US20120101046A1 (en) * 2009-03-30 2012-04-26 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase) - inhibitory peptide, and use of the peptide
NZ596783A (en) 2009-06-08 2014-01-31 Gilead Sciences Inc Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
JP5586692B2 (ja) 2009-06-08 2014-09-10 ギリアード サイエンシーズ， インコーポレイテッド アルカノイルアミノベンズアミドアニリンｈｄａｃインヒビター化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075116A (en) * 1989-04-20 1991-12-24 Lahaye Laboratories, Inc. Composition and method for treatment of macular degeneration
KR100835700B1 (ko) * 1999-08-19 2008-06-09 시그널 파머슈티컬스 인크 Ｊｎｋ억제제로서의 피라졸로안트론과 그 유도체 및 이를 함유하는 조성물
US6204270B1 (en) * 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
EP1196390A2 (en) * 2000-02-05 2002-04-17 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto

Also Published As

Publication number Publication date
NZ540187A (en) 2008-03-28
US20040092568A1 (en) 2004-05-13
WO2004041191A3 (en) 2004-12-02
TW200420290A (en) 2004-10-16
WO2004041191A2 (en) 2004-05-21
CA2504028A1 (en) 2004-05-21
AU2003286802A1 (en) 2004-06-07
KR20050061596A (ko) 2005-06-22
JP2006507307A (ja) 2006-03-02
EP1565188A2 (en) 2005-08-24
MXPA05004550A (es) 2005-07-26

Similar Documents

Publication Publication Date Title
BRPI0608152A2 (pt) formulações para tratamento ocular
BR0315939A (pt) Métodos para tratar ou prevenir degeneração macular em um paciente e maculopatia relacionada com idade, neovascularização coroidal, descolamento do epitélio de pigmento ou atrofia de epitélio de pigmento retinal e composição farmacêutica
CA2582316A1 (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
BRPI0310144A8 (pt) vitreólise farmacológica
GEP20094781B (en) Sulfonamide derivatives for the treatment of diseases
BR0302584A (pt) Combinação de brimonidina e timolol para uso oftálmico tópico
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
HUP0401568A2 (hu) Periokuláris vagy subconjunctivális adagolásra alkalmas szemészeti depó készítmények
WO2006116591A3 (en) Ophthalmic formulations comprising prednisolone acetate and tobramycin and uses thereof
AR058620A1 (es) Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo
BG63612B1 (bg) Състав и метод за профилактика и лечение на нiv идруги инфекциозни заболявания при човека
BR0315573A (pt) Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica
WO2006073786A3 (en) Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
BR0214806A (pt) Composições farmacêuticos de 5,7,14-triazatetraciclo-{10.3.1.02,11.0,4,9]-hexadeca-2(1 1),3,5,7,9-penteno
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
CN102078284A (zh) 一种含加替沙星的眼用凝胶剂及其制备方法
BR0116251A (pt) composição de lágrimas artificiais contendo uma combinação de três demulcentes
DE69227259D1 (de) Film zur lokalen arzneistoffabgabe für periodontale behandlung
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
Sheshala et al. Formulation and characterization of pH induced in situ gels containing sulfacetamide sodium for ocular drug delivery: A combination of Carbopol®/HPMC polymer
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0409882A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
CN108883081A (zh) 蛋白酶体抑制剂治疗眼部疾病的用途

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A. E 7A.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.